Difference between revisions of "Lepirudin (Refludan)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 23: | Line 23: | ||
[[Category:Direct thrombin inhibitors]] | [[Category:Direct thrombin inhibitors]] | ||
| − | [[Category:Heparin-induced thrombocytopenia medications]] | + | [[Category:Heparin-induced thrombocytopenia medications (historic)]] |
| − | [[Category:Venous thromboembolism medications]] | + | [[Category:Venous thromboembolism medications (historic)]] |
| + | [[Category:EMA approved in 1997]] | ||
[[Category:FDA approved in 1998]] | [[Category:FDA approved in 1998]] | ||
[[Category:Discontinued drugs]] | [[Category:Discontinued drugs]] | ||
Latest revision as of 01:06, 29 June 2024
Discontinued by manufacturer in 2012
General information
Class/mechanism: Direct thrombin inhibitor, binds to thrombin and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
Also known as
- Brand name: Refludan